Tongxinluo Improve High on Clopidogrel Platelet Reactivityn Patients With Coronary Heart Disease (Talent)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2012 by Shenyang Northern Hospital.
Recruitment status was  Not yet recruiting
Information provided by (Responsible Party):
Yaling Han, Shenyang Northern Hospital Identifier:
First received: November 1, 2012
Last updated: NA
Last verified: November 2012
History: No changes posted
Tongxinluo is a kind of Chinese patent drug,which could promote blood circulation.Recent reports suggested that tongxinluo's effectiveness in reducing the thrombin activity.In this prospective randomized study,all patients in control group will receive blank placebo ,all patients in test group will receive tongxinluo.All patients will be followed up for one year.

Condition Intervention Phase
Coronary Artery Disease
Drug: Tongxinluo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Study of Tongxinluo to Improve High on Clopidogrel Platelet Reactivity in Patients With Coronary Heart Disease

Resource links provided by NLM:

Further study details as provided by Shenyang Northern Hospital:

Primary Outcome Measures:
  • Platelet aggregation rate( by VerifyNow) [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Inflammation Marker (hsCRP、CD62P-CD41) [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • BT、FIB and APTT [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]
  • Major Ischemia event [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Including MI、Ischemic Stroke and all-cause mortality

  • bleeding event [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Adverse drug reaction and withdrawal rate [ Time Frame: 1 month ,1 year ] [ Designated as safety issue: Yes ]
  • Angina recurrence [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Traditional Chinese medicine angina symptoms scores [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Intra-stent thrombosis [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: November 2012
Estimated Study Completion Date: February 2014
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Conrol
Placebo,3 capsules/time,3times/day for 1 year
Experimental: Tongxinluo
Tongxinluo 3 capsules/time 3times/day for 1 year
Drug: Tongxinluo
Other Name: Tongxinluo capsule

Detailed Description:
The primary endpoint is Platelet aggregation rate( by VerifyNow) at 30 days.The secondary endpoints include inflammation marker (hsCRP、CD62P-CD41),BT、FIB and APTT at 30 days,and MI、Ischemic Stroke and all-cause mortality 、bleeding events at 1 year.

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- (1)ACS (including unstable angina pectoris, non-ST-segment elevation myocardial infarction and ST-elevation myocardial infarction) (2)Accept at least one coronary stent. (3)The age between18 and 75 . (4)High on-treatment platelet reactivity defined as an ADP-induced platelet aggregation (by VerifyNow,PRU≥236)at 24 hr after clopidogrel loading (300 ~ 600mg)or 24 hours after PCI.

(5)Informed Consent

Exclusion Criteria:

  • (1)Tongxinluo contraindication . (2)Receiving GP IIb / IIIa receptor antagonist treatment (3)Who complicate the known bleeding tendency and blood system diseases. (4)NYHA grade III ~ IV (5)Aspirin or clopidogrel allergies (6)Severe liver or kidney dysfunction (7)Pregnancy (8)Cann't accept 30 days supervision and blood proofer. (9)Other serious illness, life expectancy less than 6 months. (10) Planned surgery recently (11) PCI again within 30 days. (12) Mental diseases interfering understanding the informed consent form (13)Accept other drugs or participate in other clinical research at the same time .
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01721590

Contact: Yaling Han, MD +86-24-23922184

China, Liaoning
ShenZhou Hopital Of ShenYang Medical College Not yet recruiting
ShengYang, Liaoning, China, 110032
Contact: Lu Li, MD    13309882525      
The 463th Hospital Of PLA Not yet recruiting
ShenYang, Liaoning, China, 110042
Contact: Hongyun Zang, MD    15309885517      
Northern Hospital Not yet recruiting
Shenyang, Liaoning, China
Contact: Yaling Han, Dr    +86-24-23922184   
Principal Investigator: Yaling Han, MD         
Sub-Investigator: Yi Li, MD         
Sub-Investigator: Lei Zhang, MBBS         
Sub-Investigator: Meiling Ge, MBBS         
Sponsors and Collaborators
Yaling Han
Principal Investigator: Yaling Han, Dr Shenyang Northern Hospital
  More Information

No publications provided

Responsible Party: Yaling Han, vice president, Shenyang Northern Hospital Identifier: NCT01721590     History of Changes
Other Study ID Numbers: SYNH-20120929
Study First Received: November 1, 2012
Last Updated: November 1, 2012
Health Authority: China: Ministry of Health

Keywords provided by Shenyang Northern Hospital:
high on-treatment platelet reactivity
Coronary Heart Disease

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Heart Diseases
Myocardial Ischemia
Arterial Occlusive Diseases
Cardiovascular Diseases
Vascular Diseases processed this record on November 27, 2015